for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vincerx Pharma Inc

VINC.OQ

Latest Trade

14.85USD

Change

0.02(+0.13%)

Volume

7,771

Today's Range

14.81

 - 

15.20

52 Week Range

10.00

 - 

26.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.83
Open
14.99
Volume
7,771
3M AVG Volume
3.75
Today's High
15.20
Today's Low
14.81
52 Week High
26.70
52 Week Low
10.00
Shares Out (MIL)
17.52
Market Cap (MIL)
254.76
Forward P/E
-5.50
Dividend (Yield %)
--

Latest Developments

More

Vincerx Pharma Reports Q2 Loss Per Share Of $0.12

Vincerx Pharma Presents Clinical Data on VIP512, Its PTEFb/CDK9 Inhibitor, In Patients With Double-Hit Lymphoma At ASCO 2021

Vincerx Pharma Reports Q1 Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vincerx Pharma Inc

Vincerx Pharma, Inc., formerly Vincera Pharma, Inc., is a clinical-stage life sciences company. The Company focuses on the development and oncology knowledge to advance new therapies for the treatment of cancer. The Company’s small molecule drug program includes VIP152, a clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. Its antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.

Industry

Biotechnology & Drugs

Contact Info

260 Sheridan Avenue, Suite 400

PALO ALTO, CA

94306

United States

+1.650.8006676

https://vincerx.com/

Executive Leadership

Ahmed M. Hamdy

Chairman of the Board, Chief Executive Officer

Raquel E. Izumi

President, Chief Operating Officer, Director

Alexander Seelenberger F.

Chief Financial Officer

Tom Thomas

General Counsel, Chief Legal Officer

Hermes D. Garbaen

Chief Medical Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-2.040

2021(E)

-2.703
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-48.02
Return on Equity (TTM)
-36.76

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up